CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

Depo-Testosterone

testosterone cypionate· ingredient testosterone3-oxoandrosten (4) derivatives· TESTOSTERONE CYPIONATE 1000 mg/10mL; TESTOSTERONE CYPIONATE 100 mg/mL; TESTOSTERONE CYPIONATE 2000 mg/10mL; TESTOSTERONE CYPIONATE 200 mg/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$5.41
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per ML — the trend nobody else shows. 7 weeks.

2025-08-202026-05-20

Same-ingredient options by acquisition cost

Other testosterone products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.

ProductNADAC / MLvs this
testosterone$0.45945−$4.95
testosterone$0.61771−$4.79
AndroGel$0.65670−$4.75
Testosterone$0.91844−$4.49
Testim$2.24−$3.17
testosterone$2.97−$2.44
AZMIRO$11.19+$5.78
testosterone cypionate$11.19+$5.78

Medicare Part D coverage · CY2026

On 313 plan formularies · typical tier 2
Prior auth 68% · Step therapy 0% · Quantity limit 0% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.